|
|
Дата |
---|
22.08.2025 |
21.08.2025 |
20.08.2025 |
19.08.2025 |
18.08.2025 |
15.08.2025 |
14.08.2025 |
13.08.2025 |
12.08.2025 |
11.08.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.905
|
0.964
|
0.89
|
0.881
|
0.9699
|
0.9637
|
|
|
63 739.87
|
138.00
|
0.85
|
0.90
|
0.8801
|
0.8666
|
0.9144
|
0.8757
|
|
|
10 138.67
|
72.00
|
0.8369
|
0.97
|
0.91
|
0.8369
|
0.918
|
0.8801
|
|
|
74 497.38
|
142.00
|
0.93
|
0.97
|
0.91
|
0.902
|
1.014
|
0.93
|
|
|
35 572.22
|
185.00
|
0.88
|
0.93
|
0.949899
|
0.88
|
0.95
|
0.93
|
|
|
40 294.01
|
213.00
|
0.9418
|
1.03
|
0.9452
|
0.91
|
0.9503
|
0.93
|
|
|
49 292.26
|
116.00
|
0.92
|
0.9467
|
1.06
|
0.9216
|
1.06
|
0.966
|
|
|
34 139.05
|
153.00
|
0.95
|
1.00
|
0.91
|
0.91
|
0.979999
|
0.95
|
|
|
40 035.45
|
151.00
|
0.88
|
0.956
|
0.95
|
0.90
|
0.95
|
0.93
|
|
|
43 219.67
|
124.00
|
0.88
|
0.96
|
0.9589
|
0.8823
|
0.9589
|
0.9171
|
|
|
32 698.12
|
212.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть